| Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial D Cameron, J Brown, R Dent, C Jackisch, J Mackey, X Pivot, GG Steger, ... The lancet oncology 14 (10), 933-942, 2013 | 421 | 2013 |
| PET-CT surveillance versus neck dissection in advanced head and neck cancer H Mehanna, WL Wong, CC McConkey, JK Rahman, M Robinson, ... New England Journal of Medicine 374 (15), 1444-1454, 2016 | 366 | 2016 |
| Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others J Bartlett, J Bayani, A Marshall, JA Dunn, A Campbell, C Cunningham, ... JNCI: Journal of the National Cancer Institute 108 (9), 2016 | 122 | 2016 |
| 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial HM Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, ... The Lancet 393 (10191), 2599-2612, 2019 | 119 | 2019 |
| PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data PN Aguiar Jr, RA De Mello, P Hall, H Tadokoro, G Lima Lopes Immunotherapy 9 (6), 499-506, 2017 | 113 | 2017 |
| Economic evaluation of genomic test–directed chemotherapy for early-stage lymph node–positive breast cancer PS Hall, C McCabe, RC Stein, D Cameron Journal of the National Cancer Institute 104 (1), 56-66, 2012 | 88 | 2012 |
| COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ... The lancet oncology 21 (10), 1309-1316, 2020 | 86 | 2020 |
| Current perspective–trastuzumab PS Hall, DA Cameron European Journal of Cancer 45 (1), 12-18, 2009 | 71 | 2009 |
| Cost effectiveness modelling for health technology assessment: a practical course R Edlin, C McCabe, C Hulme, P Hall, J Wright Springer, 2015 | 68* | 2015 |
| Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer R Bell, J Brown, M Parmar, M Toi, T Suter, GG Steger, X Pivot, J Mackey, ... Annals of Oncology 28 (4), 754-760, 2017 | 67 | 2017 |
| Updated cost-effectiveness analysis of trastuzumab for early breast cancer PS Hall, C Hulme, C McCabe, Y Oluboyede, J Round, DA Cameron Pharmacoeconomics 29 (5), 415-432, 2011 | 64 | 2011 |
| AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): a randomised, double-blind, placebo-controlled … P Schmid, J Abraham, S Chan, D Wheatley, M Brunt, G Nemsadze, ... J Clin Oncol 36 (15_suppl), 1007, 2018 | 57 | 2018 |
| OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. RC Stein, JA Dunn, JMS Bartlett, AF Campbell, A Marshall, P Hall, ... Health Technology Assessment (Winchester, England) 20 (10), 1, 2016 | 56 | 2016 |
| Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial J Bartlett, P Canney, A Campbell, D Cameron, J Donovan, J Dunn, H Earl, ... Clinical oncology 25 (2), 109-116, 2013 | 50 | 2013 |
| Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. P Schmid, J Abraham, S Chan, D Wheatley, AM Brunt, G Nemsadze, ... | 48 | 2020 |
| Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladder C Blick, P Hall, T Pwint, F Al‐Terkait, J Crew, T Powles, V Macaulay, ... Cancer 118 (16), 3920-3927, 2012 | 46 | 2012 |
| Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data PS Hall, P Hamilton, CT Hulme, DM Meads, H Jones, A Newsham, J Marti, ... British journal of cancer 112 (5), 948-956, 2015 | 45 | 2015 |
| Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies? R Edlin, P Hall, K Wallner, C McCabe Value in health 17 (4), 438-444, 2014 | 41 | 2014 |
| Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. PS Hall, D Swinson, JS Waters, J Wadsley, S Falk, R Roy, T Tillett, J Nicoll, ... Journal of Clinical Oncology 37 (15_suppl), 4006-4006, 2019 | 37 | 2019 |
| A randomised controlled trial and cost-effectiveness analysis of high-frequency oscillatory ventilation against conventional artificial ventilation for adults with acute … R Lall, P Hamilton, D Young, C Hulme, P Hall, S Shah, I MacKenzie, ... Health Technology Assessment (Winchester, England) 19 (23), 1-177, vii, 2015 | 36 | 2015 |
Claire HulmeProfessor of Health Economics, University of ExeterVerified email at exeter.ac.uk
